AI Engines For more Details: Perplexity Kagi Labs You
Peptic Ulcers: Nizatidine helps heal peptic ulcers, which are open sores that develop on the inner lining of the stomach or the upper part of the small intestine. It does so by reducing the production of stomach acid, which allows the ulcer to heal.
Gastroesophageal Reflux Disease (GERD): Nizatidine is effective in managing the symptoms of GERD, including heartburn and acid reflux. It works by decreasing the amount of acid produced in the stomach, thereby reducing irritation of the esophagus.
Erosive Esophagitis: Nizatidine can also be used to treat erosive esophagitis, a condition characterized by inflammation and damage to the lining of the esophagus caused by stomach acid backing up into the esophagus.
Zollinger-Ellison Syndrome: Nizatidine may be prescribed to manage Zollinger-Ellison syndrome, a rare condition characterized by excessive production of stomach acid, leading to ulcers in the digestive system.
Non-Ulcer Dyspepsia: In some cases, nizatidine may be used to alleviate symptoms of non-ulcer dyspepsia, a condition characterized by persistent or recurrent pain or discomfort centered in the upper abdomen.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Eggerthella | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Clostridium | genus | Decreases |
| 0 | 1 | Blautia | genus | Decreases |
| 0 | 1 | Clostridium perfringens A | no rank | Decreases |
| 0 | 1 | Clostridium perfringens C | no rank | Decreases |
| 0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
| 0 | 1 | Clostridium perfringens D | no rank | Decreases |
| 0 | 1 | Clostridium perfringens B | no rank | Decreases |
| 0 | 1 | Clostridium perfringens E | no rank | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Blautia obeum | species | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Eggerthella lenta | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 1 | 0 | Clostridium perfringens | species | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0 | 0 | |
| Acne | 0.3 | 0.2 | 0.5 |
| ADHD | 0.3 | -0.3 | |
| Age-Related Macular Degeneration and Glaucoma | 0.6 | 0.6 | |
| Allergic Rhinitis (Hay Fever) | 1.2 | 1.2 | |
| Allergies | 0.9 | 0.5 | 0.8 |
| Allergy to milk products | 0.5 | 0.3 | 0.67 |
| Alopecia (Hair Loss) | 0.7 | 0.7 | |
| Alzheimer's disease | 1.5 | 1.1 | 0.36 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.9 | 0.9 | |
| Ankylosing spondylitis | 1.3 | 0.6 | 1.17 |
| Anorexia Nervosa | 0.3 | 0.9 | -2 |
| Antiphospholipid syndrome (APS) | 0 | 0 | |
| Asthma | 1.6 | 0.3 | 4.33 |
| Atherosclerosis | 0.3 | 0.3 | 0 |
| Atrial fibrillation | 1.3 | 0.3 | 3.33 |
| Autism | 2.2 | 1.9 | 0.16 |
| Autoimmune Disease | 0.2 | -0.2 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Bipolar Disorder | 0.8 | 0.3 | 1.67 |
| Brain Trauma | 0.3 | -0.3 | |
| Cancer (General) | 0.1 | -0.1 | |
| Carcinoma | 1.3 | 1 | 0.3 |
| Celiac Disease | 0.4 | 1.3 | -2.25 |
| Cerebral Palsy | 0.5 | 0.4 | 0.25 |
| Chronic Fatigue Syndrome | 1.1 | 1.2 | -0.09 |
| Chronic Kidney Disease | 1.4 | 0.5 | 1.8 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | -0.3 | |
| Chronic Urticaria (Hives) | 0.2 | 0.2 | |
| Coagulation / Micro clot triggering bacteria | 0.1 | -0.1 | |
| Cognitive Function | 1.1 | 0.2 | 4.5 |
| Colorectal Cancer | 1.5 | 0.8 | 0.88 |
| Constipation | 0.6 | 0.1 | 5 |
| Coronary artery disease | 0.4 | -0.4 | |
| COVID-19 | 1.4 | 2 | -0.43 |
| Crohn's Disease | 1.6 | 1.6 | 0 |
| Cushing's Syndrome (hypercortisolism) | 0.4 | -0.4 | |
| cystic fibrosis | 0.4 | -0.4 | |
| deep vein thrombosis | 0.1 | 0.3 | -2 |
| Depression | 2 | 1.5 | 0.33 |
| Eczema | 0.2 | 0.2 | 0 |
| Endometriosis | 1 | 0.3 | 2.33 |
| Epilepsy | 0.5 | 0.4 | 0.25 |
| erectile dysfunction | 0.5 | 0.5 | |
| Fibromyalgia | 1.2 | 0.5 | 1.4 |
| Functional constipation / chronic idiopathic constipation | 0.8 | 0.9 | -0.13 |
| gallstone disease (gsd) | 0.9 | 0.9 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | 0.5 | -4 |
| Generalized anxiety disorder | 0.7 | 0.5 | 0.4 |
| giant cell arteritis | 0.2 | -0.2 | |
| Gout | 0.3 | 0.2 | 0.5 |
| Graves' disease | 0.3 | 1 | -2.33 |
| Gulf War Syndrome | 0.3 | 0 | 0 |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 1.2 | 0.8 | 0.5 |
| Heart Failure | 0.8 | 0.1 | 7 |
| hemorrhagic stroke | 0.6 | 0.6 | |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 0.3 | 0.3 | |
| hypercholesterolemia (High Cholesterol) | 0.2 | 0.2 | |
| hyperglycemia | 0.4 | -0.4 | |
| hypersomnia | 0.1 | -0.1 | |
| hypertension (High Blood Pressure | 1.5 | 0.8 | 0.88 |
| Hypothyroidism | 0.4 | -0.4 | |
| Hypoxia | 1.1 | 1.1 | |
| IgA nephropathy (IgAN) | 0.6 | 0.6 | 0 |
| Inflammatory Bowel Disease | 1.1 | 1.2 | -0.09 |
| Insomnia | 1 | 0.7 | 0.43 |
| Intelligence | 0.5 | 0.5 | |
| Intracranial aneurysms | 0.4 | 0.4 | |
| Irritable Bowel Syndrome | 1.5 | 0.8 | 0.88 |
| ischemic stroke | 0.4 | 0.3 | 0.33 |
| Liver Cirrhosis | 1.5 | 1.1 | 0.36 |
| Long COVID | 1.1 | 1.9 | -0.73 |
| Low bone mineral density | 0.3 | -0.3 | |
| Lung Cancer | 0.7 | -0.7 | |
| ME/CFS with IBS | 0.2 | 0.6 | -2 |
| ME/CFS without IBS | 0.6 | 0.9 | -0.5 |
| Metabolic Syndrome | 1.5 | 1.3 | 0.15 |
| Mood Disorders | 1.4 | 1.2 | 0.17 |
| multiple chemical sensitivity [MCS] | 0.1 | -0.1 | |
| Multiple Sclerosis | 1.5 | 1.1 | 0.36 |
| Multiple system atrophy (MSA) | 0.1 | -0.1 | |
| myasthenia gravis | 0.2 | -0.2 | |
| neuropathic pain | 0.3 | 0.6 | -1 |
| Neuropathy (all types) | 0.4 | 0.4 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.5 | 1 | 0.5 |
| NonCeliac Gluten Sensitivity | 0.7 | 0.3 | 1.33 |
| Obesity | 1.8 | 1.8 | 0 |
| obsessive-compulsive disorder | 0.9 | 1.2 | -0.33 |
| Osteoarthritis | 0.6 | 0.3 | 1 |
| Osteoporosis | 0.8 | 1 | -0.25 |
| Parkinson's Disease | 1.2 | 1.5 | -0.25 |
| Polycystic ovary syndrome | 0.9 | 0.6 | 0.5 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.2 | |
| Premenstrual dysphoric disorder | 0.1 | 0.1 | |
| primary biliary cholangitis | 0.6 | 0.2 | 2 |
| Primary sclerosing cholangitis | 0.5 | 0.6 | -0.2 |
| Psoriasis | 0.4 | 0.3 | 0.33 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.6 | 1.2 | 0.33 |
| Rosacea | 0.2 | 0.2 | 0 |
| Schizophrenia | 1.3 | 0.9 | 0.44 |
| scoliosis | 0.3 | -0.3 | |
| Sjögren syndrome | 0.1 | 1 | -9 |
| Sleep Apnea | 1 | 0.7 | 0.43 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.5 | 0.5 | |
| Stress / posttraumatic stress disorder | 1.1 | 0.4 | 1.75 |
| Systemic Lupus Erythematosus | 0.9 | 0.4 | 1.25 |
| Tic Disorder | 0.1 | 0.6 | -5 |
| Tourette syndrome | 0.6 | 0.3 | 1 |
| Type 1 Diabetes | 0.7 | 0.8 | -0.14 |
| Type 2 Diabetes | 1.6 | 1.3 | 0.23 |
| Ulcerative colitis | 1.6 | 0.6 | 1.67 |
| Unhealthy Ageing | 1.4 | 1.4 | |
| Vitiligo | 0.6 | 0.2 | 2 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
